Case study
Make earlier, more confident
decisions in early phase
oncology trials
See how leading sponsors used Clario’s advanced data‑capture solutions in their early phase oncology trials to:
- Improve their patient’s safety
- Strengthen their data quality
- Accelerate critical go/no‑go decisions
Explore the case study that best matches your current oncology trial challenges – or, if you’re ready to move forward, connect with our experts to get started.
Power your trial with data and expertise you can trust – when decisions matter most
With smaller patient populations, compressed timelines, and high-stakes investment, sponsors need technology that delivers fast, reliable insights across imaging, cardiac safety, and patient‑reported outcomes.
Clario helps sponsors:
- Detect efficacy signals earlier with advanced imaging analytics, such as total tumor burden, data centralization and expert review
- Strengthen patient safety using centralized ECGs and near real‑time symptomatic adverse event data
- Understand patient impact more completely, including tolerability and dose‑limiting toxicities, with near real‑time eCOA insights
Early phase oncology case studies
eCOA Phase I oncology case study
By combining engaging digital eDiaries with science‑led consulting and near real‑time compliance oversight, Clario helped the sponsor gain earlier, more reliable insights that informed downstream dose selection and development strategy.
Cardiac safety and novel oncologic case study
By delivering highly precise, regulator‑ready cardiac data and analyses that were accepted by the FDA, Clario helped the sponsor mitigate QT risk early, avoid a costly dedicated QT study, and secure a favorable product label.
Detect efficacy signals earlier with Clario’s advanced oncology imaging
Site‑based imaging introduces variability, and relying only on RECIST can limit early signal detection. Clario’s advanced imaging and analytical tools – including total tumor response and tumor growth kinetics – can provide earlier, more accurate assessments of treatment response.
Protect patient safety with centralized cardiac data and expert overread
Early phase oncology trials require precise cardiac safety oversight. Shifting from site‑based or paper ECGs to Clario’s centralized ECGs with expert overreads delivers:
More consistent measurements
Fewer false inclusions
Earlier insight into potential cardiotoxicity
Download this Cardiac Safety case study to see how centralized cardiac safety monitoring enabled reliable QT assessment, avoided the need for a more costly dedicated QT study and supported FDA acceptance in a Phase I/II oncology study.
Measure patient impact in near real-time with Clario’s eCOA solution
Paper PROs delay insights when timing matters most. With Clario’s science‑led eCOA solution and accelerated setup, sponsors get accurate, near real‑time data to quickly understand:
- Tolerability levels to inform dosing decisions
- Patient-reported symptomatic adverse events
- Impact on patient burden and quality of life
Download this eCOA case study to see how Clario’s consultative approach helped guide dosing strategy, supported Phase II/III planning and enabled differentiation from the competition.
Explore what’s possible for your early phase program
Early phase oncology doesn’t allow for guesswork.
Start using Clario advanced data‑capture solutions to improve patient safety, strengthen evidence, and accelerate decision‑making with confidence.